{"id":"W4407576339","doi":"10.1038/s41467-025-56619-x","title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Clinical endpoint; Internal medicine; Phases of clinical research; Population; Neuroblastoma; Gastroenterology; Bone pain; Interim analysis; Bone marrow; Adverse effect; Minimal residual disease; Progressive disease; Surgery; Clinical trial; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001427089,0.001476429,0.001670039,0.0003792719,0.0002647031,0.0006209018,0.0008772149,0.001164938,0.003354126],"category_scores_gemma":[0.0007165478,0.0003464661,0.0009030995,0.0002784204,0.0005284056,0.0005991888,0.0003251629,0.001775893,0.0006547821],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007618404,"about_ca_system_score_gemma":0.001330124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009952674,"about_ca_topic_score_gemma":0.003507256,"domain_scores_codex":[0.9997181,0.0001686761,0.00001115655,0.00003602985,0.00002428421,0.00004166105],"domain_scores_gemma":[0.9997558,0.00004595076,0.0000485881,0.00001938592,0.00001782617,0.0001123479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7693679,0.03899824,0.0031455,0.001935398,0.001388166,0.0003903624,0.0002314503,0.002694476,0.02830822,0.0005356862,0.007203728,0.1458008],"study_design_scores_gemma":[0.8335586,0.1565159,0.003310076,0.00006365833,0.0002607431,0.0002617996,0.00003340757,0.001191594,0.001714595,0.0002101297,0.002857528,0.0000220558],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884936,0.004049886,0.0005246729,0.0006351594,0.0002062122,0.003141162,0.0009241496,0.0001342986,0.001890815],"genre_scores_gemma":[0.975902,0.005339732,0.003696808,0.001346188,0.0002778119,0.006265946,0.002724979,0.00003522368,0.004411228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003354126,"threshold_uncertainty_score":0.01122069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06358709569426185,"score_gpt":0.4778914031717435,"score_spread":0.4143043074774816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}